Cassandra Willyard If authorized, molnupiravir would be the first oral treatment for COVID-19.Credit: Merck & Co Inc/Handout/Reuters The pharmaceutical firm Merck announced last week that an antiviral pill it’s developing can cut hospitalizations and deaths among people with COVID-19 by half. The results haven’t yet been peer reviewed. But if the drug candidate, molnupiravir, is...